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ABSTRACT
Objective To assess whether vaccination against human
papillomavirus (HPV) increases the risk of miscarriage.
Design Pooled analysis of two multicentre, phase three
masked randomised controlled trials
Setting Multicentre trials in several continents and in
Costa Rica.
Participants 26 130 women aged 15-25 at enrolment;
3599 pregnancies eligible for analysis.
Interventions Participants were randomly assigned to
receive three doses of bivalent HPV 16/18 VLP vaccine
with AS04 adjuvant (n=13 075) or hepatitis A vaccine as
control (n=13 055) over six months.
Main outcome measures Miscarriage and other
pregnancy outcomes.
Results The estimated rate of miscarriage was 11.5% in
pregnancies in women in the HPV arm and 10.2% in the
control arm. The one sided P value for the primary analysis
was 0.16; thus, overall, there was no significant increase
in miscarriage among women assigned to the HPV vaccine
arm. In secondary descriptive analyses, miscarriage rates
were 14.7% in the HPV vaccine arm and 9.1% in the
control arm in pregnancies that began within three
months after nearest vaccination.
Conclusion There is no evidence overall for an association
between HPV vaccination and risk of miscarriage.
Trial registration Clinical Trials NCT00128661 and
NCT00122681.
INTRODUCTION
Human papillomaviruses (HPV) cause virtually all of
the nearly half million incident cases and quarter million deaths each year from cancer of the cervix.1 2 Randomised trials have shown that two vaccines based on
an antigen consisting of HPV L1 protein virus-like particles are highly efficacious at preventing end points
that are part of the natural course of cervical
cancer.3-5 The Gardasil vaccine targets HPV types 16
and 18, which cause 70% of cervical cancer, and types 6
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and 11, which cause genital warts. The Cervarix vaccine targets types 16 and 18. Both vaccines are licensed
in Europe, the United States, and many countries
around the world.
Because one main target population of the vaccines
is women of reproductive age, a meaningful increase in
risk of serious adverse effects on reproduction would
mitigate some of the public health benefit of reduced
morbidity and mortality during adulthood because of
lower rates of cervical cancer and its precursors. Miscarriage is the most prevalent adverse outcome of pregnancy. Although vaccines are not known to affect the
risk of miscarriage,6 Cervarix’s new AS04 adjuvant
could, in theory, cause alterations in maternal immune
function in early pregnancy.7 The magnitude of any
increased risk of miscarriage and of the set of pregnancies at increased risk would be important factors in personal decisions and public health policy on use of the
HPV vaccines. Furthermore, any increase in the baseline rate of miscarriage because of the vaccine would
raise concern that it might have other unrecognised
biological activity. On the other hand, receipt of a vaccine with no effect on miscarriage might lower a
woman’s lifetime risk of preterm delivery and infertility by reducing the need for cone excision for treatment of precancerous lesions related to HPV.8
We determined the risk of miscarriage in two independent phase three double blind randomised controlled efficacy trials of Cervarix. In a combined
analysis, we compared the risk of miscarriage in pregnancies conceived after vaccination with Cervarix or
with a hepatitis A vaccine as control. Because the
mechanisms by which the vaccine could affect pregnancies are unknown, we also do not know the specific
time at risk between conception and vaccination.
Therefore, we use a statistical test in our primary analysis that maintains statistical power when the vaccine
does have an effect, regardless of the true subset of
pregnancies at increased risk, with rigorous control of
page 1 of 7
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the chance of falsely reporting a positive conclusion
when the vaccine has no effect.
METHODS
Trials of Cervarix
We included data collected in double blinded randomised clinical trials to evaluate the efficacy of Cervarix
for prevention of cervical lesions and persistent infection with HPV types 16 and 18 from two independent
large studies. PApilloma TRIal against Cancer In young
Adults (PATRICIA)3 is a multicentre trial sponsored by
GlaxoSmithKline Biologicals (GSK). The Costa Rica
Vaccine Trial (CVT)9 is a study in Costa Rica sponsored
by the National Cancer Institute (NCI).
Origin of this report
After the planned interim analysis of PATRICIA
showed imbalance in the miscarriage rates between
the two arms, the data safety monitoring board of
CVT asked the trial statistician (SW) to prepare a
report on miscarriage based on data in both trials.
With the help of two outside consultants (AJW and
GM), the trial statistician presented a plan to the
board, acquired the required data from the independent statistician for PATRICIA (Lieven Declerck, SClinica, Brussels, Belgium), and prepared an analysis.
The results were presented separately to the data safety
monitoring board for CVT and the independent data
monitoring committee for PATRICIA. Members of
the two boards asked the statistician to prepare a manuscript for publication. The GSK Biological researchers
had opportunities to ask questions and to comment on
the research plan, results, and manuscripts, but the

Women

Women randomised (n=26 130) (49 174 person years of follow-up)

HPV vaccine (n=13 055)

Pregnancies excluded (n=19):
Ectopic (n=15)
Molar (n=4)

Pregnancies

Intrauterine pregnancies (n=2346)

Hepatitis A vaccine (n=13 075)

Pregnancies excluded (n=12):
Ectopic (n=10)
Molar (n=2)
Intrauterine pregnancies (n=2364)

Excluded (n=560):
Recent pregnancy (n=508)
Missing date of last menstrual
period (n=52)

Excluded (n=551):
Recent pregnancy (n=489)
Missing date of last menstrual
period (n=62)

Pregnancies included in analysis (n=1786;
1594 women had one pregnancy, 95 had ≥2)

Pregnancies included in analysis (n=1813;
1633 women had one pregnancy, 89 had ≥2)

Miscarriages (n=197;
184 women had one, six had ≥2)

Miscarriages (n=176;
166 women had one, five had ≥2)

Fig 1 | Follow-up through data freeze points (20 Dec 2007 for CVT and 31 Jan 2008 for PATRICIA)
for women and pregnancies leading to 373 miscarriages. In CVT three women received wrong
vaccination (one in HPV group and two in hepatitis A group) and were classified according to
intention to treat; one woman randomised twice was excluded. Recent pregnancies were
defined as those that began within one year of data freeze point
page 2 of 7

CVT statistician and the outside consultants prepared
reports for the monitoring boards and, with the named
authors, prepared this manuscript independently.
Participants in the analysis
Eligible women between ages 15 (PATRICIA) or 18
(CVT) and 25 consented to take part and were randomised to receive three doses of vaccine, at baseline and
at one and six months. Women received either the
HPV 16/18 vaccine formulated with the AS04 adjuvant system or a control hepatitis A vaccine consisting
of 720 ELISA units of inactivated viral antigen with
Alum, formulated in 0.5 ml doses. Each woman underwent a pregnancy test on a urine sample before each
vaccination; vaccination was discontinued when the
result was positive. Enrolled women with childbearing
potential agreed to use birth control from one month
before the first vaccination until two months after the
last vaccination, per study protocol. Women are being
followed at least annually for a period of four years
from first vaccination.
Figure 1 shows follow-up through the data freeze
points of 31 January 2008 (PATRICIA) and 20 December 2007 (CVT) among the 26 130 women and 2567
reported pregnancies included in this analysis. Additional details on the two studies are available
elsewhere. 3 9
Collection of information on pregnancy
Both studies actively monitored participants’ safety,
including information on pregnancies and their outcomes throughout the entire study period. Specifically,
immediately after learning that a woman was pregnant, study staff completed a form documenting the
expected delivery date based on report of her last menstrual period. They also contacted the woman after her
expected delivery date to learn the pregnancy outcome. Staff coded information on gynaecological history, date of last menstrual period, date of end of
pregnancy, gestational age, whether the delivery was
vaginal or caesarean, and delivery outcome and
weight, length, sex, Apgar score, and outcome of the
baby. Women were instructed to report serious
adverse events related to pregnancies at any time during follow-up. Any reported abnormality of pregnancy
or delivery and any medical condition of the baby at
birth were documented with appropriate forms and
reported according to the local regulations and the
good clinical practice guidelines. All adverse events
were coded with MEDRA preferred codes for PATRICIA and with the Spanish edition of ICD-10 (international classification of diseases, 10th revision) for
CVT. The date of the last menstrual period was
abstracted from charts or inferred from information
supplied by the woman. We calculated the estimated
date of conception as 14 days after the last period. We
defined miscarriage as loss of pregnancy within
20 weeks after the last period. Diagnosis of miscarriage
was by self report and clinical judgment of the investigator; a positive pregnancy test result followed by a
negative result was usually considered to be loss of
BMJ | ONLINE FIRST | bmj.com
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Table 1 | Pregnancy outcomes in pooled data from 26 130 women in two trials of vaccine
against human papillomavirus (HPV) types 16 and 18 (with hepatitis A vaccine as control).
Figures are numbers (percentages)

Miscarriages

HPV vaccine

Hepatitis A vaccine

Total

197 (11.0)

176 (9.7)

373 (10.4)

Gestation at miscarriage (weeks):
0-6

43

38

81

7-12

108

107

215

13-20
Induced abortions*

44

30

74

127 (7.1)

128 (7.1)

255 (7.1)

Stillbirths

15 (0.8)

13 (0.7)

28 (0.8)

Live births

1401 (78.4)

1449 (79.9)

2850 (79.2)

≤33

30

41

71

34-36

75

83

158

Gestation at live birth (weeks):

≥37
Ongoing pregnancies

1295

1325

2620

46 (2.6)

47 (2.6)

93 (2.6)

Gestation at last contact in ongoing pregnancies (weeks):
≤20

15

24

39

>20

31

23

54

1786

1813

3599

Total pregnancies

*Information on induced abortion collected only in those countries where it is legal.

Fraction of pregnancies
ending in miscarriage

pregnancy. We excluded six molar and 25 ectopic
pregnancies from all analyses because their causes
are likely to be different from most miscarriages. We
collected data on induced abortions only in those
countries where they are legal. (See appendix 1 on
bmj.com for further details on collection of data relating to pregnancy.)

0.20
Difference (HPV–HAV)

HAV

HPV
0.16
0.12
0.08
0.04
0.00
-0.04
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720

Days between nearest vaccination and estimated conception
Count of miscarriages
HPV
24 18 16 12 9 14
HAV
11 10 13 14 12 13
Pregnancies at risk
153 124 117 108 104.5 77.5
HPV
133 109.5 131 120.5 103 96
HAV

11
19

11
11

165.5

121.5

176.5

134.5

13
20

13
11

11
12

20
11

12
9

129

144

161.5

139.5

104.5

136

117

124.5

107.5

92

Fig 2 | Miscarriage rates for both arms and differences according to time between nearest
vaccination and estimated date of conception. Of 3599 pregnancies included in analysis, 187
(5.2%) had estimated conception date before nearest vaccination. Estimations of conception
assume that ovulation occurs on day 14 after last menstrual period, though 10% of cycles
have ovulation at day 24 or later.13 Among 187 pregnancies with conception ostensibly before
vaccination, many had conception dates only a few days before vaccination (median 10 days).
Given that all pregnant women had negative hCG test results at time of vaccination (based on
highly sensitive β hCG assays), most subsequent pregnancies had probably been conceived
after relatively late ovulations and conception had occurred after vaccination. Thus, these data
do not provide useful data on the question of vaccine safety before conception (HAV=hepatitis
A vaccine)
BMJ | ONLINE FIRST | bmj.com

Statistical analysis
Ongoing pregnancies and induced abortions—To reduce
the number of ongoing pregnancies in the analysis,
which would require additional statistical assumptions, we excluded all pregnancies with estimated conception dates less than one year before the data lock
point; for pregnancies included in the analysis, we
included all information available at the time of analysis. Each woman received one to three doses of vaccine. We calculated the days between dates of each
vaccination and dates of estimated conception; we
used dates of first vaccination dose, most recent vaccination dose before the estimated conception date, and
vaccination dose nearest to (whether before or after)
the estimated conception dates as three different origins of time scales. For miscarriage analyses we examined the effect of vaccination in subsets of pregnancies
defined by time between conception and nearest vaccination. We also analysed the chance of any pregnancy and pregnancy ending in live birth by time
after first vaccination.
Rates of miscarriage—We used the ratio of pregnancy
losses before 20 weeks’ gestational age to total pregnancies, with a correction for pregnancies and induced abortions that might have ended in miscarriage (see appendix
2 on bmj.com), as the definition of the rate of miscarriage. We calculated rates of miscarriage for subsets of
pregnancies defined by time between vaccination and
conception. We present graphs showing risk of miscarriage by arm and the difference between them for pregnancies conceived at various times since vaccination.
The pattern of arm specific rates by time between vaccination and conception might help to distinguish whether
a difference is caused by a higher rate in the HPV vaccine arm or a reduced rate in the control arm.
Permutation test to address lack of knowledge of time of
conception during which vaccination might confer risk—A
standard test of the effect of vaccination on risk of miscarriage requires specification of the timing of pregnancies that might be affected by vaccination—for
example, the vaccine might affect only those pregnancies with a conception date within eight weeks of the
vaccination date. Specifying the wrong set of pregnancies for analysis can reduce power substantially compared with an analysis based on the correctly specified
set of pregnancies. Our test statistic, therefore, is the
lowest P value among several tests of the same hypothesis in overlapping subsets of pregnancies defined by
time between vaccination and conception. Our null
hypothesis was that the vaccine confers no additional
risk of miscarriage for pregnancies conceived at any
time before or after vaccination. The alternative
hypothesis is that the vaccine confers additional risk
of miscarriage for a subset of pregnancies defined by
time between vaccination and conception. We used a
permutation test, sometimes called a randomisation
test, to obtain the distribution of the test statistic
under the null hypothesis. Tests use one sided P values
because a lower miscarriage rate in the Cervarix arm
would not be a safety concern. A P value of 0.025 is the
standard for significance. This procedure has
page 3 of 7
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Table 2 | Overall and subgroup analyses of pregnancy outcome* by permutation tests of whether rate of miscarriage in HPV
vaccine arm is greater than in hepatitis A vaccine arm
HPV vaccine

Hepatitis A vaccine

Category and
subgroup

No of pregnancies

Miscarriage rate (%)

No of pregnancies

Miscarriage rate (%)

P value (one sided)†

All pregnancies

1708.5

11.5

1727

10.2

0.16

972.5

10.6

990

9.0

0.12

736

12.8

737

11.8

0.69
0.77

Subset of pregnancies
Study:
PATRICIA
CVT

Maternal age at conception (years):
≤20

519.5

9.4

531

9.8

21-23

561.5

11.6

602.5

11.1

0.26

≥24

627.5

13.2

593.5

9.6

0.17

Gestational age at which pregnancy was reported (weeks after estimated conception):
<8

513.5

16.9

569.5

12.3

0.13

≥8

1192

9.2

1153.5

9.1

0.19
0.52

No of vaccinations before estimated time of conception:
1

154

11.0

142.5

11.2

2

381.5

13.4

370.5

11.3

0.28

3

1132

11.0

1181.5

9.6

0.44

Interval between estimated date of conception and nearest vaccination (days):
<90

488

13.7

456.5

9.2

0.033

90‡

394

14.7

373.5

9.1

0.031

≥90

1220.5

10.7

1270.5

10.5

0.68

Subset of miscarriages§
Gestation at miscarriage (weeks):
0-6

1708.5

2.5

1727

2.2

0.59

7-12

1708.5

6.3

1727

6.2

0.12

13-20

1708.5

2.6

1727

1.7

0.13

PATRICIA=papilloma trial against cancer in young adults; CVT=Costa Rica vaccine trial.
*Induced abortions counted as half pregnancy in columns of counts and in denominator of rates.
†Permutation test statistic is minimum P value for difference in rates for all pregnancies conceived during selected windows of time between
vaccination and estimated date of conception (EDC). By restricting pregnancies considered in permutation test, we reduced number of intervals
considered and focused on those most likely to be at risk if vaccine has effect.
‡Estimated date of conception on or after date of vaccination but less than 90 days after nearest vaccination.
§Rates are percentages of all pregnancies with miscarriage in specified interval of gestational age.

reasonable power for a wide range of pregnancy subsets that might be at increased risk of miscarriage, albeit
with less power than the standard test with the subset at
increased risk specified correctly (see supplemental
tables 1a-1e in appendix 6 on bmj.com). (Further
details about the permutation test and the power of
permutation and standard tests for alternative hypotheses are in appendices 3 and 4 on bmj.com.)
Subgroup and sensitivity analyses—We conducted subgroup analyses thought a priori to have possible importance by applying the permutation method separately
for PATRICIA and CVT; maternal age at estimated
conception date of ≤20, 21-23, and ≥24 years; pregnancies that came to the attention of investigators within
eight weeks and more than eight weeks after the last
menstrual period; and the number of vaccinations
received by the participant before the estimated date
of conception of the pregnancy. We also applied the
permutation test on subsets of pregnancy defined by
time between vaccination and estimated conception
and on subsets of miscarriages defined by gestational
age. Because the pregnancy, not the woman, is the unit
of observation, we checked whether smoking, parity,
page 4 of 7

age at enrolment, or age at conception was associated
with the assigned group. As no evidence of association
was seen (data not shown) we did not perform an analysis adjusting for covariates.
Total pregnancies and live births—We compared the
rates of total pregnancy and of live births by time
between first vaccination and possible date of conception. Further details about the methods for comparison
of rates of total pregnancy and live birth are in appendix 5 on bmj.com.
RESULTS
There were 4710 pregnancies with an estimated date of
conception after enrolment among 26 130 randomised
women. We excluded 25 ectopic and six molar pregnancies; 19 of these 31 (61%) were in the HPV vaccine
arm. We excluded 997 pregnancies with estimated
date of conception less than one year from the data
freeze date (including 76 (7.6%) miscarriages and 3
(0.3%) stillbirths) and 114 pregnancies with missing
date of last menstrual period (among which there
were 14 (12%) miscarriages and 2 (2%) stillbirths). Of
the remaining 3599 intrauterine pregnancies, 2850
BMJ | ONLINE FIRST | bmj.com
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Table 3 | Rates of miscarriage by study arm for pregnancies
conceived within specified interval from nearest vaccination.
Figures are numbers (percentages) and estimates of effect
(difference in percentage, ratio)
Time interval
(days) around
vaccination

HPV

Hepatitis A

Estimates of
effect

−30-−1

8 (10.3)

7 (9.9)

0.4, 1.04

−30-29

32 (14.3)

18 (9.3)

5.1, 1.55

−30-59

50 (14.7)

28 (9.3)

5.4, 1.58

−30-89

66 (14.5)

41 (9.7)

4.8, 1.50

−30-849*

196 (12.2)

175 (10.7)

1.5, 1.14

0-29

24 (16.6)

11 (8.9)

7.6, 1.85

0-59

42 (16.0)

21 (9.2)

6.9, 1.75
5.8, 1.60

0-89

58 (15.4)

34 (9.6)

0-849*

188 (12.3)

168 (10.8)

1.5, 1.14

30-59

18 (15.4)

10 (9.4)

6.0, 1.63
4.7, 1.47

30-89

34 (14.7)

23 (10.0)

30-849*

164 (11.9)

157 (10.9)

0.9, 1.09

60-89

16 (13.9)

13 (10.5)

3.4, 1.33

60-849*

146 (11.5)

147 (11.0)

0.5, 1.05

90-849*

130 (11.3)

134 (11.1)

0.2, 1.02

120-849*

118 (11.2)

120 (11.0)

0.3, 1.02

180-849*

95 (10.8)

95 (10.5)

0.3, 1.03

360-849*

60 (12.6)

45 (9.8)

2.7, 1.28

*Maximum number of days between nearest vaccination and conception
date is 849.

(79.2%) ended in live births (table 1), of which 2620
(91.9%) were term births (37 weeks or more); 373
(10.4%) ended in miscarriage; and 28 (0.8%) in stillbirth. No induced abortions were recorded in CVT

(which was conducted in a country where they are
not legal); 255 induced abortions were reported in
PATRICIA (12.1% of pregnancies in PATRICIA and
7.1% among all pregnancies). When the data file was
frozen for this analysis we had no information on the
final outcome of 93 (2.6%) pregnancies; 39 (1.1%) had
not reached 20 weeks’ gestation and remained at risk of
miscarriage at the last contact. The estimated rates of
miscarriage are 11.5% and 10.1% in the HPV and
hepatitis A vaccine arms, which are within the range
of international rates. 10
Result of primary test
The one sided P value for the primary permutation test
was 0.16, with the nearest vaccination as the reference
date (table 2); the more familiar two sided P value was
0.29. Most (58%) of the miscarriages occurred between
7 and 12 weeks’ gestation, consistent with published
literature. 4 The permutation test result was also not significant in groups defined by the two trials, by maternal
age at estimated conception, by whether the pregnancies were restricted by gestational age at confirmation
of pregnancy or by number of vaccinations the participant received before the estimated date of conception;
or for subsets of gestational age at miscarriage.
Rates of miscarriage for subsets of pregnancies defined by
time between nearest vaccination and conception
Figure 2 shows the counts of miscarriages and pregnancies and the rates by arm according to the time between
nearest vaccination and date of estimated conception.
Table 3 summarises the underlying rates for selected
subsets of pregnancies. The difference was not

Table 4 | Miscarriages by time between nearest vaccination and estimated conception. Figures are numbers (percentages) of miscarriages in each vaccine
group by gestation at miscarriage, with estimates of effect (difference in percentage, ratio)*
Time interval
(days) around
vaccination

0-6 weeks

7-12 weeks

13-20 weeks

HPV

Hep A

Estimates of
effect

−30-0

2 (2.6)

2 (2.8)

−0.3, 0.91

2 (2.6)

4 (5.6)

−3.1, 0.46

4 (5.1)

1 (1.4)

−30-29

6 (2.7)

4 (2.1)

0.6, 1.30

16 (7.2)

11 (5.7)

1.5, 1.27

9 (4.0)

3 (1.5)

2.5, 2.61

−30-59

6 (1.8)

6 (2.0)

−0.2, 0.88

31 (9.1)

16 (5.3)

3.8, 1.71

12 (3.5)

5 (1.7)

1.9, 2.12
0.7, 1.30

HPV

Hep A

Estimates of
effect

HPV

Hep A

Estimates of
effect
3.7, 3.64

−30-89

12 (2.6)

9 (2.1)

0.5, 1.24

39 (8.6)

21 (5.0)

3.6, 1.73

14 (3.1)

10 (2.4)

−30-849†

43 (2.7)

38 (2.3)

0.4, 1.15

108 (6.7)

107 (6.6)

0.2, 1.03

44 (2.7)

29 (1.8)

1.0, 1.54

0-29

4 (2.8)

2 (1.6)

1.1, 1.70

14 (9.7)

7 (5.7)

4.0, 1.70

5 (3.4)

2 (1.6)

1.8, 2.12

0-59

4 (1.5)

4 (1.7)

−0.2, 0.87

29 (11.1)

12 (5.2)

5.8, 2.11

8 (3.1)

4 (1.7)

1.3, 1.75

0-89

10 (2.7)

7 (2.0)

0.7, 1.34

37 (9.8)

17 (4.8)

5.0, 2.04

10 (2.7)

9 (2.5)

0.1, 1.04

0-849†

41 (2.7)

36 (2.3)

0.4, 1.16

106 (6.9)

103 (6.6)

0.3, 1.05

40 (2.6)

28 (1.8)

0.8, 1.46

30-59

0 (0.0)

2 (1.9)

−1.9, 0.00

15 (12.8)

5 (4.7)

8.1, 2.72

3 (2.6)

2 (1.9)

0.7, 1.36
−0.9, 0.71

30-89

6 (2.6)

5 (2.2)

0.4, 1.19

23 (9.9)

10 (4.3)

5.6, 2.28

5 (2.2)

7 (3.0)

30-849†

37 (2.7)

34 (2.4)

0.3, 1.13

92 (6.7)

96 (6.7)

0.0, 1.00

35 (2.5)

26 (1.8)

0.7, 1.40

60-89

6 (5.2)

3 (2.4)

2.8, 2.16

8 (7.0)

5 (4.0)

2.9, 1.73

2 (1.7)

5 (4.0)

−2.3, 0.43

60-849†

37 (2.9)

32 (2.4)

0.5, 1.22

77 (6.1)

91 (6.8)

−0.7, 0.89

32 (2.5)

24 (1.8)

0.7, 1.40

90-849†

31 (2.7)

29 (2.4)

0.3, 1.12

69 (6.0)

86 (7.1)

−1.1, 0.84

30 (2.6)

19 (1.6)

1.0, 1.66

120-849†

30 (2.9)

25 (2.3)

0.6, 1.25

60 (5.7)

77 (7.0)

−1.3, 0.81

28 (2.7)

18 (1.6)

1.0, 1.62

180-849†

23 (2.6)

18 (2.0)

0.6, 1.32

53 (6.0)

61 (6.8)

−0.7, 0.89

19 (2.2)

16 (1.8)

0.4, 1.22

360-849†

11 (2.3)

10 (2.2)

0.0, 1.06

39 (8.2)

27 (5.9)

0.0, 1.39

10 (2.1)

8 (1.7)

0.0, 1.2

*Excludes one woman with irregular menses and two women with missing date of last menstrual period.
†Maximum number of days between nearest vaccination and conception date is 849.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Women of reproductive age are a target for vaccines against human papillomavirus (HPV)
Generally, non-live vaccines administered around the time of conception or during pregnancy
do not increase the risk of miscarriage
Evidence about the effect of the antigen and adjuvant used in Cervarix on the risk of
miscarriage is limited

WHAT THIS STUDY ADDS
There is no overall effect of vaccination with Cervarix on risk of miscarriage
A small increase seen in risk of miscarriage in the subgroup of pregnancies conceived within
three months of vaccination is compatible with chance, but does raise concern for a vaccine
that is likely to be administered to millions of women of reproductive age

significant (13.7% in HPV vaccine arm, 9.2% in hepatitis A vaccine arm; P=0.033; table 2) by the permutation
test for pregnancies with estimated date of conception
less than 90 days from nearest vaccination. The difference in estimated miscarriage rates between arms
among pregnancies conceived nearer vaccination
reflects higher rates in the hepatitis A arm and lower
rates in the HPV arm than in the other pregnancies.
For an estimated date of conception less than 90 days
after vaccination, most of the difference between miscarriage counts in the groups was for miscarriages at
7-12 weeks’ gestation (20 of the total difference of 24,
table 4). For pregnancies that began 90 days or more
after vaccination, the miscarriage rates are similar in the
two arms (counts of 130 (HPV) and 134; rates of 10.7%
and 10.5%). Results with other time scales also did not
show greater risk in the HPV arm (data not shown).
Total pregnancies and live births

The rates of total pregnancies and live births were similar in the two arms, with P values from the permutation
test of 0.42 for total pregnancies and 0.23 for live births
(see supplementary figs 1a and 1b in appendix 5 on
bmj.com).
DISCUSSION

We found no significant increase in miscarriage rate in
women who had received the Cervarix vaccine against
HPV compared with women assigned to a control arm.
We found no evidence of a decrease either in total new
pregnancies or in new pregnancies ending in live birth
in the HPV arm, and, thus, no evidence that the HPV
vaccine affected loss of undetected pregnancies.
Among our subgroup analyses, we found a non-significant imbalance in estimated miscarriage rates for
pregnancies conceived within three months after the
nearest vaccination, the time frame with the highest
prior probability of an effect. We found no sign of a
detrimental effect of HPV vaccination on miscarriage
rates for pregnancies conceived beyond three months
after vaccination, even though power to detect an effect
with a relative risk of about 2 during this time period
was substantial.
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Strengths and weaknesses
Despite the reassurance from our overall results and
from studies of other vaccines, we looked carefully
for signs of increased risk of miscarriage because
even a small effect could cause a large number of miscarriages among the millions of sexually active women
worldwide whom we expect to receive the HPV vaccine. We used the permutation test to maintain power
to find an effect across a range of subsets of pregnancies
possibly at increased risk, while strictly controlling the
chance of a false positive result that could lead to overinterpretation of an apparent effect found a posteriori
in some subsets of pregnancies.
The absence of a vaccine effect is consistent with other
information about risk of miscarriage from vaccination
with Cervarix and Gardasil or other vaccines before or
during pregnancy. The May 2008 update of guidelines
from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention states that risk from vaccinating pregnant
women is “primarily theoretical,” and that no evidence
has shown a risk with vaccines that are not live.11 ACIP
guidelines for Gardasil, which uses the same type of
antigen as Cervarix but with a different adjuvant, do
not recommend use during pregnancy, though they
note that the limited data on vaccination during pregnancy do not show a causal association with adverse
outcomes or adverse events in the developing fetus.12
The power of our study to detect a moderate effect of
the vaccine in subsets of pregnancies, the absence of
established effects of other vaccines on miscarriage,
and the low prior probability that Cervarix has an
effect on miscarriage combined with the limited statistical evidence of effect lead us to conclude that the
HPV vaccine probably does not cause miscarriage.
The observed variation in the differences between
rates of miscarriage between arms in the subset of pregnancies conceived closer to vaccination is consistent
with a small effect of vaccination or statistical noise.
The similarity of miscarriage rates in the two arms for
conceptions that began beyond three months after vaccination provides some reassurance that there is no
long term effect of the vaccine.
Nonetheless, we cannot completely rule out the possibility of an increased risk among pregnancies conceived within three months of vaccination. It is
unlikely that postmarketing surveillance will find
small but important effects of vaccination on miscarriage because of the difficulties of ascertaining miscarriages in comparable unvaccinated women and
determining timing of last menstrual period in vaccinated women, which is needed to investigate whether
any effect is restricted to pregnancies conceived near
vaccination. We recommend further analyses of data
on miscarriage from randomised controlled trials to
help to clarify further whether vaccines have any effect
on miscarriage: pooling reported and as yet unreported data on both vaccines with the VLP antigen—
that is, Cervarix and Gardasil—and pooling all data
from Cervarix and other GSK vaccines containing
the same novel adjuvant as Cervarix.
BMJ | ONLINE FIRST | bmj.com

RESEARCH

Affiliations of the Costa Rica Vaccine Trial (CVT) group
Proyecto Epidemiológico Guanacaste, Fundaci ón INCIENSA, San
José, Costa Rica: Mario Alfaro (cytologist), Manuel Barrantes (field
supervisor), M Concepcion Bratti (co-investigator), Fernando Cárdenas
(general field supervisor), Bernal Cortés (specimen and repository
manager), Albert Espinoza (head, coding and data entry), Yenory Estrada
(pharmacist), Paula Gonzalez (co-investigator), Diego Guillén
(pathologist), Rolando Herrero (co-principal investigator), Silvia E
Jimenez (trial coordinator), Jorge Morales (colposcopist), Lidia Ana
Morera (head study nurse), Elmer Pérez (field supervisor), Carolina
Porras (co-investigator), Ana Cecilia Rodriguez (co-investigator), Maricela
Villegas (clinic MD).
University of Costa Rica, San José, Costa Rica: Enrique Freer
(director, HPV diagnostics laboratory), Jose Bonilla (head, HPV
immunology laboratory), Sandra Silva (head technician, HPV diagnostics
laboratory), Ivannia Atmella (immunology technician), Margarita Ramírez
(immunology technician).
US National Cancer Institute, Bethesda, MD, USA: Allan
Hildesheim (co-principal investigator), Douglas R Lowy (HPV virologist),
Nora Macklin (trial coordinator), Mark Schiffman (co-project officer and
medical monitor), John T Schiller (HPV virologist), Mark Sherman (QC
pathologist), Diane Solomon (medical monitor and QC pathologist),
Sholom Wacholder (statistician).
SAIC, NCI-Frederick, Frederick, MD, USA: Ligia Pinto (head, HPV
immunology laboratory), Alfonso Garcia-Pineres (scientist, HPV
immunology laboratory).
Women’s and Infants’ Hospital, Providence, RI, USA: Claire Eklund
(QC cytology), Martha Hutchinson (QC cytology).
DDL Diagnostic Laboratory, Voorburg, Netherlands: Wim Quint
(HPV DNA testing), Leen-Jan van Doorn (HPV DNA testing).
Contributors: SW, AW, and GM designed the pooled analysis. PG, ACR,
RH, AH, and BB were responsible for data collection. SW, BEC, AW, GM,
and BB analysed the data. SW wrote the paper. SW, BEC, AW, GM, PG, BB,
AH, ACR, DS, RH, and MS interpreted the data. SW, BEC, AW, GM, PG, AH,
ACR, DS, RH, and MS critically reviewed all material. SW is guarantor.
Funding: The CVT trial is sponsored and funded by the National Cancer
Institute (N01-CP-11005) with support from the NIH Office for Research
on Women’s Health and conducted in agreement with the Ministry of
Health of Costa Rica. PATRICIA is funded by GSK Biologicals. GSK
Biologicals contributed data from PATRICIA to the analysis, and
commented on aspects of the trial at the design stage and after the
results were shared with investigators of both trials, with the permission
of the Data Safety Monitoring Board of CVT. GSK Biologicals had no role in
study design and the collection, analysis, and interpretation of data from
CVT in this paper, or in the writing of the article. GSK Biologicals took no
part in the decision to submit an article for publication. The pooled
analysis reported here was supported by the Intramural Research
Programs of the National Cancer Institute (NCI) and the National Institute
of Environmental Health Sciences, both parts of the National Institutes of
Health.
Competing interests: Vaccine was provided for CVT by GSK Biologicals,
under a clinical trials agreement with NCI. GSK also provided support for
aspects of the trial associated with regulatory submission needs of the
company under FDA BB-IND 7920. Douglas Lowy and John Schiller from
NCI are named inventors on US government owned HPV vaccine patents
that are licensed to GSK and Merck, and so are entitled to limited royalties
as specified by federal law. None of the other NCI and Costa Rica coauthors have any potential conflicts of interest to report. The researchers
are completely independent from the non-government funders and
sponsors. After a planned interim analysis, including safety review, of
PATRICIA in December 2006,3 the data and safety monitoring board
(DSMB) of CVT requested an assessment of possible effects of the
vaccine on miscarriages by performing a pooled post hoc analysis of data
from the two parallel trials. GSK provided data on pregnancy for this

BMJ | ONLINE FIRST | bmj.com

miscarriage analysis from PATRICIA 3 to the statistician for CVT (SW). Two
outside consultants (GM and AW), who are experts in reproductive
epidemiology, helped in the preparation of the analysis and report. Both
the data and safety monitoring board and the independent data
monitoring committee (IDMC), which oversees CVT and PATRICIA trials,
respectively, recommended that NCI statistician prepare a manuscript
describing the results for publication in the scientific literature. GSK
scientists provided background information and data from PATRICIA, and
provided suggestions on the methods, analysis and interpretation. CVT
investigators from NCI and Costa Rica prepared this manuscript with
input from the expert and consultants. GSK scientists commented on
draft manuscripts, but the named authors made the final decisions about
its content.
Ethical approval: The NIH Office of Human Subjects Research granted an
exemption from institutional review board review to NCI investigators to
use data from PATRICIA for this pooled analysis. The study protocol,
amendments, informed consent, and other information regarding
PATRICIA that required pre-approval were reviewed by a national,
regional or investigational centre independent ethics committee or
institutional review board.
Data sharing: No additional data available.
1
2

3

4

5

6

7

8

9

10
11

12

13

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA
Cancer J Clin 2005;55:74-108.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S.
Human papillomavirus and cervical cancer. Lancet
2007;370:890-907.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM,
et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types
16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 2007;369:2161-70.
FUTURE II Study Group. Quadrivalent vaccine against human
papillomavirus to prevent high-grade cervical lesions. N Engl J Med
2007;356:1915-27.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM,
Leodolter S, et al. Quadrivalent vaccine against human
papillomavirus to prevent anogenital diseases. N Engl J Med
2007;356:1928-43.
Centers for Disease Control and Prevention. ACIP: guidance for
vaccine recommendations in pregnant and breastfeeding women.
CDC, 2008. www.cdc.gov/vaccines/recs/acip/rec-vac-preg.htm.
Goldhaber MK, Fireman BH. The fetal life table revisited:
spontaneous abortion rates in three Kaiser Permanente cohorts.
Epidemiology 1991;2:33-9.
Sjoborg KD, Eskild A. Vaccination against human papillomavirus—
an impact on preterm delivery? Estimations based on literature
review. Acta Obstet Gynecol Scand 2009;88:255-60.
Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C,
Solomon D, et al. Rationale and design of a community-based
double-blind randomized clinical trial of an HPV 16 and 18 vaccine in
Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
Wilcox AJ. Fertility and pregnancy: an epidemiologic perspective.
Oxford University Press, 2010.
Centers for Disease Control and Prevention. Guidelines for
vaccinating pregnant women—human papillomavirus. CDC, 2008.
www.cdc.gov/vaccines/pubs/preg-guide.htm#hpv.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H,
Unger ER. Quadrivalent human papillomavirus vaccine:
recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 2007;561-24.
Baird DD, McConnaughey DR, Weinberg CR, Musey PI, Collins DC,
Kesner JS, et al. Application of a method for estimating day of
ovulation using urinary estrogen and progesterone metabolites.
Epidemiology 1995;6:547-50.

Accepted: 26 October 2009

page 7 of 7

